FOLH1 and anemia: Nuclear medicine and bone-seeking radiolabeled pharmaceuticals have demonstrated encouraging results in metastatic PCa treatment, particularly since the discovery of the prostate-specific membrane antigen (PSMA) protein as a beneficial diagnostic and therapeutic target (28); However, multiple adverse effects, including anemia, changes in blood parameters, liver enzyme elevation, nephrotoxicity, fatigue, nausea, and dry mouth, are reported in a considerable proportion of patients (20).